BioMarin (BMRN): Voxzogo holds near $1B while the royalty that cushions it runs out — and the next seven months decide whether it is still a growth asset. Voxzogo has grown into a roughly $1B product on the strength of a franchise with no competition, and that phase ends now. Two FDA decisions in the first half of 2027 do the deciding: infigratinib on 4 February, which would put an oral competitor into a market where weekly Yuviwel already undercuts Voxzogo's daily injections, and Voxzogo's own hypochondroplasia decision on 30 May, the only new growth left once achondroplasia matures. BioMarin reaches both with less room to expand in its higher-priced markets and with a royalty on the rival product that expires in May 2030. Until now the shares have been paid for by growth; from here they are paid for by labels, payer files and a market ceiling closer than the price allows for.

BioMarin is stuck in the arithmetic of its own success. Voxzogo was the first approved drug for achondroplasia, the most common form of dwarfism, and it is already near the ceiling of who can take it: about 24,000 eligible children across BioMarin's markets, 2,400 of them American, a pool diagnosed at or before birth that barely grows. Only the share treated can. Hypochondroplasia, the replacement on offer, is a milder disease that has to be found in school-age children and paid for by insurers who will ask what a daily injection buys a mildly short child. The royalty from the weekly rival is the only thing bridging the two, and it stops dead on 20 May 2030.

So the franchise holds its sales and loses its economics. Voxzogo sales sit near $1.06B to 2032 in our model while modeled pre-tax franchise contribution falls about 10%, from $474M in 2029 to $426M in 2031. Halving hypochondroplasia starts costs $1.17 a share and doubling ex-US price erosion $1.10; a 46% US oral share costs only $0.32. Our DCF base of $45.54 is 20% below the $57.23 close, and closing that gap needs Voxzogo near $1.9B by 2032 — more than the entire achondroplasia market will be worth that year, roughly $1.45B across all three drugs (Exhibit 3). The price is a bet that hypochondroplasia outgrows the disease Voxzogo was approved for, in a population that is still largely undiagnosed. We hold it near $1.06B. It is not a call on BMRN.

Exhibit 1

Franchise sales and contribution across the royalty expiry

Flat sales, falling contribution. Modeled product sales are flat from 2029 to 2031 (+$4M), but the Yuviwel royalty ends on 20 May 2030. Modeled pre-tax contribution falls by $48M (−10%) from its 2029 peak and is still 9% below it in 2032.

Modeled sales, royalty and contribution, $MRoyalty ends 20 May 203003006009001,2001,01820261,04420271,09520281,11120291,08120301,06520311,0762032418474430AchondroplasiaHypochondroplasiaBMN 333Yuviwel royaltyContribution proxyContribution without BMN 333
View data
$M2026202720282029203020312032
Achondroplasia sales1,0001,0151,033997936872811
Hypochondroplasia sales042264123190254
Voxzogo product sales1,0001,0191,0561,0611,0591,0621,065
BMN 333 sales00000311
Yuviwel royalty182639502200
Contribution proxy418433461474446426430
Contribution proxy without BMN 333418433461474446426429

Contribution = 40% of Voxzogo and BMN 333 sales plus the royalty, pre-tax; modeled, not reported profit. Full notes: Appendix A3.

Source: Clinaptis achondroplasia market model; switching model for hypochondroplasia; franchise valuation (modeled).


Exhibit 2

What each stress costs the franchise, $ per share

Hypochondroplasia uptake and ex-US price erosion are the largest single risks, at $1.17 and $1.10 a share; a 3% annual fall in US net prices costs $0.53 and a 46% US oral share only $0.32. Together the first two cost $2.20 a share, about 16% of the franchise’s modeled $13.65 a share.

Loss in BMRN value, $ per share2032 sales2032 contrib.2029→31House baseBase case$1,065M$430M−10%Half HCH + double ex-US price−$2.20$835M$338M−19%No hypochondroplasia−$2.34$811M$329M−22%Half hypochondroplasia starts−$1.17$938M$380M−16%Double ex-US price erosion−$1.10$955M$386M−13%US net price −3% a year−$0.53$1,018M$411M−11%46% US oral share by 2031−$0.32$1,036M$418M−10%
View data
Scenario (change from our base)BMRN value, $/sh2032 Voxzogo sales2032 contributionContribution change 2029→2031
House base—$1,065M$430M−10%
Half HCH starts + double ex-US price erosion−$2.20$835M$338M−19%
No hypochondroplasia−$2.34$811M$329M−22%
Half hypochondroplasia starts−$1.17$938M$380M−16%
Double ex-US price erosion−$1.10$955M$386M−13%
US net price −3% a year−$0.53$1,018M$411M−11%
46% US oral share by 2031−$0.32$1,036M$418M−10%
No BMN 333 (footnote only)−$0.04$1,074M$429M−10%

Doubled ex-US erosion: developed markets −6% a year, rest of world −4%. The US price case cuts all four US drugs 3% a year from 2027, which also trims the royalty. 8.5% discount rate, 22% tax, 193.7M shares. Full notes: Appendix A3.

Source: Clinaptis achondroplasia market model and franchise valuation (modeled, not observed data).


1. The achondroplasia market has a ceiling

About 24,000 children in BioMarin's markets are eligible (BioMarin, JPM 2025): about 2,400 in the US, 5,300 in Europe, Japan, Australia and Canada, and 16,300 elsewhere. Ascendis independently puts the US at about 2,600 children, 30% of them treated when Yuviwel launched in April. Achondroplasia is diagnosed at or before birth, so the pool barely grows; only the share treated can.

At 70% of children treated, the whole US market is worth about $500M at a ~$300k net price. Yuviwel is widening the market rather than only taking share: Ascendis's ~340 US enrollments are about three times the Voxzogo patients BioMarin's 85% retention implies it lost, so most appear to be new to treatment (our inference; enrollments and retention are different counts). Our model allocates a capped ~$0.5B US market among the competing drugs.

BioMarin calls Europe, Japan, Australia and Canada "highly penetrated", and they are where Yuviwel and infigratinib launch first. The remaining two-thirds of eligible children are in Latin America, the Middle East and Asia, where prices run about a third lower and orders are lumpier. In our market model, Voxzogo's sales in developed markets outside the US fall from about $540M to $300M by 2032, while the rest of the world rises from about $220M to $380M.

Exhibit 3

The achondroplasia market plateaus at ~$1.45B from 2032; Voxzogo peaks at ~$1.03B in 2028 and the entrants take the growth

Worldwide achondroplasia product sales by drug, $M. Voxzogo here is achondroplasia only; its hypochondroplasia sales (~$254M in 2032) are excluded.

1,09220261,15620271,28020281,35920291,40820301,43520311,44820321,45120331,44720341,4372035Voxzogo 673BMN 333 31Yuviwel 374Infigratinib 359100010151033997936872811758712673Voxzogo peaks ~$1.03B (2028)

US net price flat at $312k; ex-US −3% a year in developed markets and −2% elsewhere. BMN 333 is a token share from 2031. Constant FX (EUR 1.10).

Source: Clinaptis achondroplasia market model (modeled); BioMarin and Ascendis disclosures.


Exhibit 4

The US nears its ceiling; the rest of the world holds 68% of eligible children and stays under-treated

• The US and EU/JP/AUS/CAN reach 69–74% of eligible children treated by 2035, close to their ceilings.
• The rest of the world reaches only 28%: the largest remaining untreated pool, at lower prices.

Share of eligible children treated (all drugs); column width = eligible childrenStreet-style 2030–31 sales for the three drugs would need 124–227% of eligible US children0%50%100%2026: 43%2035: 69%733US2,400 (10%)2026: 59%2035: 74%untreated 1,385EU/JP/AUS/CAN5,280 (22%)2026: 12%2035: 28%untreated 11,813Rest of world16,320 eligible (68%)Treated 2026Added by 2035 (market model)Untreated in 2035

Treated counts include all drugs. Model ceilings: 70% US, 75% EU/JP/AUS/CAN, 30% rest of world.

2035 is the model’s base case, with treatment ceilings of 70% (US), 75% (EU/JP/AUS/CAN) and 30% (rest of world).

The Street-style range applies published 2030–31 forecasts to net prices of $240–370k a patient-year.

Source: BioMarin JPM 2025 (eligible population); Ascendis August 2026 deck and Q3 2026 call; BioMarin Q3 2026 call; Clinaptis achondroplasia market model (modeled).


2. Hypochondroplasia offsets achondroplasia erosion

Without hypochondroplasia, Voxzogo sales peak at $1,033M in 2028 and fall to $811M in 2032. Measured from $1,000M in 2026, three regional forces explain the change:

  • US achondroplasia revenue falls by about $107M. US net price is held flat. The decline is share lost to Yuviwel and oral infigratinib in a market capped near 2,400 eligible children.
  • Developed markets outside the US lose about $243M. Europe, Japan, Australia and Canada are already well treated, the entrants launch there first, and prices fall about 3% a year.
  • Rest of world adds about $161M as treatment spreads in Latin America, the Middle East and Asia, at prices about a third lower.

Exhibit 5

Voxzogo sales 2026 to 2032: what holds them flat

Achondroplasia alone falls 19% by 2032, and hypochondroplasia (+$254M) more than replaces it, taking sales to ~$1.07B. Rest-of-world growth (+$161M) covers the US decline (−$107M); hypochondroplasia more than covers the erosion in Europe, Japan, Australia and Canada (−$243M).

$1,000M2026−$107MUS−$243MEU/JP/AUS/CAN+$161MRest of world+$254MHypochondroplasia$1,065M2032

Hypochondroplasia: US $154M, ex-US $100M. Excludes BMN 333 (~$11M in 2032) and the royalty.

Source: Clinaptis achondroplasia market model; switching model for hypochondroplasia (modeled; not observed data); BMRN Q3 2026 guidance.

View data
Component$M
20261,000
US−107
EU/JP/AUS/CAN−243
Rest of world+161
Hypochondroplasia+254
20321,065

3. Where the value sits

The two largest risks in Exhibit 2 are the net price Voxzogo earns outside the US and how many children with hypochondroplasia start paid treatment.

Ex-US net price: one of the two largest risks

More than 75% of Voxzogo revenue is earned outside the US, much of it through national price negotiations and large government orders. In our market model, the ex-US price per patient-year declines steadily: 3% a year in developed markets (EU, Japan, Australia and Canada) and 2% a year in the rest of the world. The same rates apply to all three drugs, and no cut is tied to a competitor's launch.

The price stress reaches both indications, because hypochondroplasia is priced at the same regional Voxzogo revenue per patient. Doubling the rate of decline (to 6% and 4% a year) costs $1.10 a share, about the same as halving hypochondroplasia starts ($1.17).

  • Launch. Ascendis plans the first EU launch of Yuviwel in Germany in the first quarter of 2027. A European Commission decision is expected in the fourth quarter of 2026, after a positive CHMP opinion.
  • Assessment. Under AMNOG, the manufacturer's own price applies for the first six months. The G-BA decides on added benefit within six months of market entry.
  • Negotiated price. The price negotiated with the statutory insurers applies retroactively from the seventh month after market entry.
  • Visibility. Under a rule that runs to 30 June 2028, a company with research activity in Germany can elect to keep its negotiated price confidential. Ascendis's research organisation is in Heidelberg, so it could plausibly qualify. If it makes that election, the Yuviwel price will not appear in German price lists or in other countries' price comparisons.

For a first-quarter 2027 launch, the G-BA decision would land around the third quarter of 2027. The negotiated Yuviwel price would follow afterwards but take effect from that seventh month.

How a Yuviwel price could reach Voxzogo. External reference pricing compares the price of the same product across countries, so a German Yuviwel price does not enter any other country's price calculation for Voxzogo. It can reach Voxzogo's net price in three ways:

  • Voxzogo's own German agreement. The annual cost of comparable drugs is one of the criteria in German price negotiations, and either party can terminate an agreement after a year. If the EU approves hypochondroplasia, Germany would reassess Voxzogo for the new indication and renegotiate its price across indications, as happened after the under-two extension in 2024. We estimate that reassessment around 2028, when Yuviwel could already be a comparator. Of 20 orphan drugs Germany reassessed in 2019–24 after their sales crossed the threshold, 65% lost their added-benefit rating, and the renegotiated price fell by 23.2% on average (range 0–62%); Voxzogo was one of them (Initiate Consultancy, ISPOR Europe 2024). A one-off cut of that size in Germany is larger than several years of our base-case decline of 3% a year, which is why we treat the 2028 renegotiation as the largest single ex-US price event. A permanent 23.2% cut from 2028 on 10–20% of our developed ex-US Voxzogo sales (both indications) costs $0.09–0.17 a share, before any spillover to markets that reference German prices.
  • Markets that compare drugs within an indication. Switzerland reviews every listed drug every three years and whenever its indication is extended. Each review compares the drug with its own price in nine reference countries, including Germany, and with other drugs for the same disease.
  • Tender and contract renewals in markets that buy centrally.

Voxzogo's German sales passed the €30M orphan threshold within its first full year, which triggered a full benefit reassessment (Appendix Exhibit A4). BioMarin does not report revenue by country, so we cannot weight Germany precisely.

Neither company expects a fast Yuviwel rollout outside the US. BioMarin cites long market-access lead times, and Ascendis still sells mostly through named-patient and early-access programs. Voxzogo's own contracts and renegotiations can transmit price pressure before many patients switch.

The trigger is revenue per child, net of order timing. Children treated grew about 17–20% or more in each of the first three quarters, against nine-month revenue growth of 10%, so revenue per treated child fell roughly 7–8% (our arithmetic; period-end patient counts are a rough denominator). Management attributes the gap to order timing, and the global figure also reflects country mix and net price. Our model already assumes a 4–5% annual decline from price and mix. A persistent decline beyond that range after the deferred orders ship would lead us to steepen ex-US price erosion.

Our 3% annual developed-market decline represents Voxzogo's German renegotiation, the reference pricing that follows and tender renewals, with Yuviwel as a new comparator. Appendix Exhibit A4 sets out the German timeline.

Hypochondroplasia: approval likely, uptake uncertain

Hypochondroplasia is a milder relative of achondroplasia, caused by different mutations in the same gene (FGFR3). In the randomized Phase 3 CANOPY-HCH-3 trial (81 children aged 3 to 17), Voxzogo increased annualized growth velocity by 2.33 cm a year over placebo at 52 weeks (95% CI 1.85–2.82; p<0.0001), with no treatment-related serious adverse events reported. That is a larger placebo-adjusted effect than Voxzogo showed in its separate achondroplasia trial (1.57 cm a year), though this is not a direct comparison. The investigator-sponsored Phase 2 extension enrolled 13 children who had already gained more than 1.6 cm a year in the core study. Their growth velocity stayed above baseline for three years. That responder-only sample gives little basis for estimating how many children will stay on daily injections after launch. Following the positive topline in May, BioMarin's US application has an FDA date of 30 May 2027, and the EMA has validated its European filing.

Our model assumes:

  • US: launch in 2027, building over three years to 150 new patients a year (25, 75 and 125 in 2027–2029, then 150 a year). That is about 675 cumulative US starts by 2032.
  • Ex-US: launch in 2028, building over four years to 400 a year. That is about 1,200 cumulative ex-US starts by 2032.
  • Discontinuation: 12% of treated hypochondroplasia patients a year, flat. Achondroplasia uses a different structure: age-specific attrition plus children ageing out as growth plates close. The two indications do not share a discontinuation rate in the model.
  • Price: the same regional Voxzogo revenue per patient-year as achondroplasia: $312k in the US, and an ex-US average that falls as treatment spreads to lower-priced markets.

BioMarin puts about 14,000 children with hypochondroplasia in its global footprint as potentially addressable, a figure management has described as conditional on diagnosis. It compares that with about 24,000 children with achondroplasia in the same markets. Our ~1,875 cumulative starts by 2032 would be about 13% of the 14,000. In May, BioMarin reported identifying 90% more patients and a 70% fall in age at identification. Its November update still gave no count of diagnosed children who could start treatment at launch. The US is harder to size:

  • Published prevalence estimates range from 1 in 15,000 to 1 in 75,000 live births, and the condition is often underdiagnosed.
  • The average US age at diagnosis is about 4.5 years.
  • With about 3.6M US births a year, those estimates imply roughly 50–240 affected children born each year. (Our arithmetic, not a published figure.) At the low end, our 150 annual US starts are three times the roughly 50 new cases a year, so the model depends on diagnosing and treating children already born.

Sustaining 150 US starts a year requires diagnosing school-age children and payer coverage for a milder phenotype, where the clinical case for daily injections may look weaker than in achondroplasia.

After approval, uptake depends on:

  • Label breadth: the age range and any severity or genotype criteria will define who can start.
  • Payer coverage: the Cigna and ConnectiCare policies we reviewed exclude hypochondroplasia under the current achondroplasia-only labels. The first updated policies will show whether height, severity or genetic-confirmation requirements narrow access below the diagnosed population. Ascendis's CEO has made the general point for this condition: in many countries, reimbursement for a costly therapy has to be justified by the clinical benefit.
  • Persistence: whether families of milder children stay on daily injections at our assumed 12% annual dropout will take longer to measure.

Later diagnosis will slow adoption relative to achondroplasia. Achondroplasia is usually diagnosed before or at birth, while hypochondroplasia growth curves separate only after the first year. In France's national rare-disease registry, birth prevalence is 1.31 per 100,000 for hypochondroplasia against 3.27 for achondroplasia, the most recent birth cohorts are barely recorded yet, and the authors note that milder cases may remain undiagnosed. The launch depends on finding and diagnosing school-age children. The trial enrolled only genetically confirmed children at least 2 SD below average height; if labels and payers follow, part of the diagnosed population will not qualify. Children also start later, with fewer growing years left, and families of milder children may persist less with daily injections. Ascendis expects to enroll the first patients in a Phase 3 trial of Yuviwel monotherapy in hypochondroplasia in the fourth quarter of 2026, and BridgeBio is running a Phase 3 of oral infigratinib (NCT06873035). Weekly or oral dosing counts for more in a milder condition.

A one-year delay costs $0.51 a share; halving the starts costs $1.17. Hypochondroplasia revenue of about $22M in 2028, $64M in 2029 and $123M in 2030 keeps the franchise on our path.

Exhibit 6

Hypochondroplasia approval looks likely in May 2027; ~$250M by 2032 depends on diagnosis and payer uptake

Our base needs about 1,575 children on treatment by 2032, 11% of the ~14,000 BioMarin calls addressable, to reach ~$254M. Mark reported revenue against $22M (2028), $64M (2029) and $123M (2030).

Children on treatment at year end (bars, left)Revenue, $M (line, right)0$0600$1001,200$2001,800$3002027(25 starts)252028(125 starts)1472029(275 starts)4042030(400 starts)7562031(500 starts)1,1652032(550 starts)1,576$4M$22M$64M$123M$190M$254MUS (launch 2027; 150 starts a year from 2030)Ex-US (launch 2028; 400 starts a year by 2032)Modeled revenue
View data
Modeled202720282029203020312032
US new starts2575125150150150
Ex-US new starts050150250350400
US treated, year end2597210335445542
Ex-US treated, year end0501944217201,034
Total treated, year end251474047561,1651,576
Hypochondroplasia revenue, $M42264123190254

12% annual discontinuation (modeled). Diagnosis rates, label breadth and payer coverage are not yet known.

Source: BioMarin; Nature Reviews Endocrinology; Clinaptis switching model (modeled).


4. Voxzogo vs Yuviwel and infigratinib: what a lost US patient costs

The cost of a lost US patient depends on the competing drug and the royalty expiry. Until 20 May 2030, a switch to Yuviwel returns a royalty of 20% of Yuviwel's US net sales (18% in the EU, Brazil and South Korea), which keeps about $21–24 of every $100 of lost US revenue. A switch to infigratinib returns nothing. A new start on a competitor costs only what that child would have earned had they started on Voxzogo. A patient moving from Yuviwel to infigratinib can cut the royalty without touching Voxzogo sales. Pushing oral infigratinib to 46% of US treated patients by 2031, against 34% in our base, costs BioMarin $0.32 a share (Exhibit 2). It takes US achondroplasia Voxzogo revenue to about $100M in 2032, against about $130M in our base and $450M with no competition at all. At an 80% margin, the same oral-share stress costs $0.63 a share and the ex-US price stress $2.28, preserving the ranking.

Exhibit 7

A Yuviwel switch returns about $22 per $100 of lost US revenue until May 2030; an oral switch returns nothing

For every $100 of Voxzogo revenue lost to Yuviwel in the US, BioMarin collects about $22 in royalty (range $21–24). That covers about half of the ~$40 of profit lost if Voxzogo costs fall away with the patient, and under a third of the ~$80 lost if they do not. Switches to infigratinib, and all switches after 20 May 2030, return nothing.

Kept per $100 of Voxzogo revenue lost, until 20 May 2030After May 2030$0$20$40$60$80$100~$40 lost at 40%~$80 lost at 80%Yuviwel, US20% royalty on Yuviwel net sales~$22$0Yuviwel, EU, Brazil, South Korea18% royalty~$20$0Yuviwel, other countriesoutside royalty territories$0$0Infigratinib, anywhereno economic link$0$0Royalty kept (midpoint)Profit lost and not recovered, at a 40% margin

The range depends on relative net prices, which neither company discloses: the low end uses our model's prices (Yuviwel $330k, Voxzogo $312k), the high end equal gross-to-net discounts. The 80% line is an illustrative incremental margin.

Source: BMRN 8-Ks (Aug–Sep 2026) and Ascendis 6-K on the settlement; Clinaptis estimates.

View data
Where the patient goesKept per $100 lost, to May 2030After May 2030
Yuviwel, US$21–24$0
Yuviwel, EU, Brazil, South Korea$18–22$0
Yuviwel, other countries$0$0
Infigratinib, anywhere$0$0

BioMarin reported that about 90% of US children treated with Voxzogo remained on it at the end of July and about 85% at the end of September, measured from Yuviwel's launch, while the monthly pace of switching slowed through the third quarter. The two are consistent, because retention is cumulative. Switchers cited injection fatigue or a wish to try weekly dosing. Children under two, the one age group in which Voxzogo is the only approved therapy, were the majority of US new starts. Management expects that advantage to last at least the next couple of years. Ascendis expects pivotal data from its infant trial in the third quarter of 2027; any label expansion would then need its own regulatory review.

Enrollments, approved reimbursement, paid starts and persistent patients are four different counts, and BioMarin stops reporting US switching metrics from the fourth quarter of 2026. Infigratinib's FDA date (4 February 2027) and Voxzogo's full approval (28 February 2027) matter mainly through label breadth and monitoring burden. No trial has shown one drug to be better than another, so families will choose on injection burden (365 injections a year, 52, or none), evidence depth, monitoring and access.

Exhibit 8

Achondroplasia: no drug has shown superiority, so choice turns on dosing burden

Placebo-adjusted gains are 1.57, 1.49 and 1.74 cm/yr, each against its own placebo arm, with overlapping confidence intervals. Infigratinib’s widely quoted 2.10 is the unadjusted difference. No head-to-head trial exists.

0.511.522.5InjectionVosoritide (Voxzogo)111-301, ages 5–<15, daily injection1.57 (1.22–1.93)InjectionNavepegritide (Yuviwel)ApproaCH, ages 2–11, weekly injection1.49 (1.05–1.93)OralInfigratinibPROPEL 3, ages 3–<18, daily oral (adjusted)1.74 (1.31–2.17)2.10 unadjusted (hollow), not comparablePlacebo-adjusted gain in annualized height velocity at week 52, cm/yr (95% CI)

Baseline-adjusted (ANCOVA). Trial designs differ, so indirect contrasts cannot exclude differences of about ±0.6 cm/yr. Only Voxzogo has randomized data under age 2.

Source: Voxzogo label (111-301); ApproaCH, JAMA Pediatrics 2026; PROPEL 3, NEJM 2026 and BridgeBio disclosures.

View data
Drug, trialcm/yr95% CI
Vosoritide (Voxzogo), 111-301, ages 5–<15, daily injection1.571.22–1.93
Navepegritide (Yuviwel), ApproaCH, ages 2–11, weekly injection1.491.05–1.93
Infigratinib, PROPEL 3, ages 3–<18, daily oral (adjusted)1.741.31–2.17
Infigratinib, unadjusted difference2.101.38–2.81

Ascendis Q3 update (12 November 2026). Ascendis's third-quarter release reported about 340 unique US Yuviwel enrollments from nearly 150 prescribers through 31 October, with more than 80% approved for reimbursement. Yuviwel revenue was €16M in the quarter, double the second quarter. Management again named three sources of patients (switches from daily therapy, patients returning to treatment and first-time starts) without quantifying them, and gave no paid-patient count. It also said it will report enrollments for about four to five quarters and then move to revenue-only disclosure. BioMarin plans to stop reporting US switching from the fourth quarter of 2026 and to focus its updates on Voxzogo revenue.

5. What replaces the Yuviwel royalty?

The royalty ends on 20 May 2030, when Ascendis's licence becomes fully paid-up and royalty-free; from then on, Yuviwel's growth earns BioMarin nothing. Our model has the royalty at $50M in 2029, $22M in the part-year 2030 and zero from 2031. Product sales are flat over 2029–2031 (+$4M), so modeled pre-tax contribution falls from $474M to $426M as the royalty goes. Hypochondroplasia then lifts it slowly, to $430M in 2032 and $442M by 2035, still 7% below the 2029 peak.

Of 2032 contribution, about $325M comes from achondroplasia, $102M from hypochondroplasia and $4M from BMN 333. Halving hypochondroplasia starts cuts 2032 contribution to $380M; removing BMN 333 barely moves it ($429M). From 2031 to 2035 the hypochondroplasia ramp (+$84M of contribution) slightly more than offsets further achondroplasia erosion (−$80M). Weaker hypochondroplasia uptake lowers contribution; BMN 333 adds to it only if it beats Voxzogo in Phase 3. (Our arithmetic from the franchise run.)

The clinical question. BioMarin says the highest dose tested in healthy adults gave more than 13 times the free CNP exposure of another long-acting CNP. ASPEN tests whether that exposure becomes faster growth in children at a tolerable dose, or whether the response flattens. The 2027 Phase 2 readout compares 30 children across three BMN 333 doses with 10 on Voxzogo. It will inform dose selection and whether a Phase 3 superiority study is worth running; BioMarin has not disclosed its threshold. With a control arm of 10, we would favor a consistent dose-response and tolerability over the best-looking arm. Whether any Phase 2 growth advantage persists will need Phase 3 evidence.

The commercial question. Winning Yuviwel patients is a separate test: Yuviwel already doses weekly, and ASPEN compares BMN 333 with Voxzogo, not Yuviwel. Management has said weekly convenience alone would be a weaker commercial proposition. If BMN 333 rests mainly on convenience, it competes for patients Yuviwel already serves, and arrives several years later.

Modelling assumptions. We give BMN 333 only a token share until Phase 3 shows it beats Voxzogo. We assume a Phase 3 readout around 2029, a US launch in 2031 and a developed ex-US launch in 2032. It takes 5% of US new starts and 3% of developed ex-US new starts, and converts 1–2% a year of BioMarin's own Voxzogo patients, priced at parity with Voxzogo. That gives about $11M of 2032 sales ($31M in 2035) and $0.05 a share against the case without BMN 333, with no separately modeled development cost.

Exhibit 9

Nothing replaces the royalty in full: contribution falls 10% and recovers only slowly as hypochondroplasia outgrows achondroplasia erosion

Contribution falls from $474M in 2029 to $426M in 2031 and reaches $442M by 2035, still 7% below the peak. By 2032, 25% of modeled contribution comes from hypochondroplasia and BMN 333, forecasts rather than approved products.

Modeled pre-tax contribution, $M015030045060020262027202820292030203120322033203420354744264422032 contribution: $430MAchondroplasia $325M · HCH $102MBMN 333 $4M (token share)Achondroplasia (40%)Yuviwel royalty (100%, to 20 May 2030)Hypochondroplasia (40%)BMN 333 (40%)Total contribution
View data
$M2026202720282029203020312032203320342035
Achondroplasia (40%)400406413399374349325303285269
Yuviwel royalty182639502200000
Hypochondroplasia (40%)029264976102124144160
BMN 333 (40%)000001481013
Total contribution418433461474446426430435439442
Without BMN 333418433461474446426429433436437

2033–35 from the market model; BMN 333 launch timing is our assumption.

Source: Clinaptis achondroplasia market model and franchise valuation; switching model for hypochondroplasia (modeled).


6. What would change the forecast

  • Hypochondroplasia paid starts. The label on 30 May 2027, the first payer policies, and revenue against the $22M / $64M / $123M path for 2028–2030.
  • Realized Voxzogo net price outside the US. The German Yuviwel price from the seventh month after launch, if Ascendis publishes it; then Voxzogo's own German renegotiation after hypochondroplasia is approved in Europe, which is what reference-pricing markets would pick up.
  • BMN 333's ability to defend contribution after the royalty. In the 2027 ASPEN readout, growth velocity by BMN 333 dose and whether any dose exceeds the Voxzogo control. BioMarin has not disclosed its threshold for pursuing Phase 3 superiority.

Exhibit 10

Franchise signposts and the assumption each one tests

The largest modeled sensitivities are ex-US net price, including whether a German Yuviwel price reaches Voxzogo, and paid hypochondroplasia starts after the 30 May 2027 FDA decision.

Dated eventExpected window or monitoring itemRegulatoryregulatory Clinical dataclinical Commercialcommercial Pricingpricing Contractual datecontractual
TimingEvent and evidence to examineDriver it moves and value at stake
Q4 2026EC decision expectedRegulatoryEC decision on YuviwelLabel age range; confirms the German launch dateEx-US net priceDouble ex-US price erosion: −$1.10/sh
Q4 2026First patients (Ascendis plan)Clinical dataAscendis Phase 3 of Yuviwel in hypochondroplasiaFirst enrollment in a monotherapy trial; sets the earliest date a competitor could reach the HCH labelHypochondroplasia paid startsNot separately valued; bears on HCH share after 2030
Jan–Feb 2027ExpectedCommercialBMRN FY2027 guidanceWhether HCH is included; how much deferred international volume (incl. ~$70M at risk of slipping from Q4) lands in 2027; underlying achondroplasia growth; treated-patient growth against revenueAll fourSeparates order timing and HCH from underlying demand
4 Feb 2027FDA action dateRegulatoryInfigratinib FDA decisionAge range; phosphate or eye monitoring in the label; launch timingAchondroplasia volumeA 46% US oral share by 2031: −$0.32/sh (Exhibit 2)
28 Feb 2027FDA action dateRegulatoryVoxzogo full approvalFinal label claims, adult-height wording, long-term outcomesAchondroplasia volumeNot separately valued; a narrower label or new monitoring would weaken new-start share
Q1 2027Ascendis planPricingYuviwel German launchLaunch date starts the AMNOG clock; manufacturer’s own price for months 1–6Ex-US net priceStarts the ex-US price test
~Q3 2027About month 6 (statutory)RegulatoryG-BA added-benefit decision on YuviwelBenefit rating against the comparator; sets up the price negotiationEx-US net priceSignals the depth of the German discount
From month 7Retroactive (statutory)PricingNegotiated Yuviwel price in GermanyThe negotiated price, unless Ascendis elects confidentiality (§ 130b Abs. 1c SGB V, agreements to 30 Jun 2028); tender and contract renewals elsewhereEx-US net priceDouble ex-US price erosion: −$1.10/sh
30 May 2027FDA action dateRegulatoryHypochondroplasia FDA decisionApproval; label age range and any severity or genotype criteriaHypochondroplasia paid startsNo hypochondroplasia: −$2.34/sh; one year later: −$0.51/sh
2H27After approvalCommercialHypochondroplasia launchLaunch timing; diagnosis and testing programsHypochondroplasia paid startsOne year later: −$0.51/sh
From launchMonitoringCommercialFirst payer policiesPrior-authorization criteria such as height thresholds or genetic confirmationHypochondroplasia paid startsHalf the modeled starts: −$1.17/sh
From launchMonitoringCommercialPaid hypochondroplasia startsPaid starts, not enrollments or approvals; persistence against our 12% a year dropoutHypochondroplasia paid startsHalf the modeled starts: −$1.17/sh
Q3 2027Ascendis planClinical dataAscendis infant (reACHin) pivotal dataEfficacy and safety under age two; any label would need a separate regulatory reviewAchondroplasia volumeNot separately valued; tests Voxzogo’s under-two advantage, the source of most US new starts
2027UndatedClinical dataASPEN Phase 2 dose-response (BMN 333)Dose-response above Voxzogo; Phase 3 decisionPost-2030 defenceNo BMN 333: −$0.05/sh
Quarterly2028–2030CommercialHypochondroplasia revenueReported revenue against the ~$22M / $64M / $123M path for 2028 / 2029 / 2030Hypochondroplasia paid startsHalf the modeled starts: −$1.17/sh; with double ex-US price erosion: −$2.20/sh
~2028After EU HCH approvalPricingVoxzogo German re-assessment and renegotiationNew G-BA assessment for hypochondroplasia, then a new German price for all indications, with Yuviwel as a comparator; reference-pricing markets follow Voxzogo’s German priceEx-US net priceDouble ex-US price erosion: −$1.10/sh
20 May 2030ContractualContractual dateYuviwel royalty endsNo further royalty on switched patients; every lost patient is lost in fullPost-2030 defenceIn our base: modeled contribution falls ~$48M (10%) from 2029 to 2031

Dates not stated by a company are our judgment. A stress on several rows is one stress.

Source: BMRN, Ascendis and BridgeBio disclosures; G-BA; Clinaptis models (modeled).


We would lower modeled hypochondroplasia starts if the label or the first payer policies narrow access. We would steepen the ex-US price decline if Voxzogo's own German renegotiation shows a concession that other markets could reference.

How to read the 2027 Voxzogo guide. The January–February guide needs hypochondroplasia and deferred orders separated from underlying achondroplasia growth:

  • Does it include hypochondroplasia? Management has left that open, given the 30 May FDA date and a launch weighted to the second half.
  • How much deferred international volume does it assume lands in 2027? A large Voxzogo order moved from the third quarter into the fourth. Separately, a batch of about $70M of orders, a little more than half of it Voxzogo, may slip from the fourth quarter into early 2027. BioMarin also cited worsening customer liquidity in the Middle East as a second reason for the 2026 guidance cut.
  • What is left for underlying achondroplasia growth once those two are removed?

Compare global treated-patient growth with revenue growth (17% against 12% in the third quarter). The gap has persisted for three quarters (see §1). If it outlasts the deferred orders, a guide that assumes it closes in full is assuming mix and price hold. The Ascendis royalty is now reported inside BioMarin's combined "royalty and other revenues" line, so it cannot serve as a standalone measure unless BioMarin breaks it out. A strong first quarter of 2027 could reflect order recovery rather than demand.

7. BioMarin beyond Voxzogo

How large Voxzogo can grow explains more of the gap between our DCF and the price than the franchise's modeled stresses do (Exhibit 13). The rest of the valuation turns on how long the legacy ERT business holds and whether 2027 earnings meet the Street.

In our base, revenue peaks at about $5.2B in 2031 and falls to about $4.7B by 2035. The two Amicus products add about $1.4B by 2035, but the legacy ERT and PKU products give back about $0.65B, because we expect Vimizim and Palynziq to lose exclusivity from 2032. Vimizim holds near $950M to 2031, then falls about 17% a year to about $460M by 2035, the competitive case in our ERT model; Palynziq falls 15% a year (Appendix B).

Exhibit 11

Revenue peaks at ~$5.2B in 2031 and falls to ~$4.7B by 2035: the Amicus products add ~$1.4B, but Vimizim and Palynziq lose exclusivity from 2032

BioMarin total revenue by product, $M. 2025 reported; 2026 is nine months reported plus a fourth-quarter estimate; 2027–35 Clinaptis base case. 2026–35 growth: total 2.3% a year; Amicus products 15.4%; Voxzogo +0.9%; legacy ERT, PKU and other −3.6%. Copper marks: FactSet consensus.

Amicus close (2Q26)Vimizim, Palynziq LOE (2032, assumed)3,2212025A3,8512026E4,4162027E4,6662028E4,8692029E5,0062030E5,1682031E5,0192032E4,9052033E4,8072034E4,7062035EVoxzogo 1,072Galafold 1,081Pombiliti + Opfolda 878Vimizim 460Palynziq 379Naglazyme 448Other enzymes 344Royalty and other 44FactSet consensus

Amicus products set about 20% below management's peak targets. Vimizim falls about 17% a year from 2032 to our ERT model's competitive case; Palynziq 15% a year from 2032; Galafold US generics in 2037 (Teva settlement). Royalty and other includes the Yuviwel royalty to May 2030. Other enzymes = Aldurazyme, Brineura, Kuvan, Roctavian. Consensus: FactSet via Google Finance, 17 Nov 2026 (2028–29 not shown).

Source: BioMarin 10-K FY25, 10-Qs and Ex. 99.1 releases 1Q–3Q26; Clinaptis base case.


Where we differ from consensus. Our revenue is close to consensus for 2027 ($4.42B against FactSet's $4.44B) but 10% below it in 2030–31 and 21% below by 2035 ($4.7B against $6.0B). We have no product-level consensus, so the split is our reading. The 2030–31 gap ($0.5–0.6B) comes before any modeled loss of exclusivity, so it reflects three things: we hold Voxzogo near $1.06B because the achondroplasia market is capped (section 1); we set the Amicus products' peaks about 20% below management's targets (~$1.4B for Galafold, ~$1.2B for Pombiliti + Opfolda), and in 2035, still growing, they are about 25% below; and we model no pipeline revenue. From 2032 the gap widens to $0.8–1.4B as Vimizim and Palynziq lose exclusivity in our model; Vimizim alone is about $0.49B lower in 2035 than if it held its 2031 level. On EPS we are 7% below consensus in 2027 and level in 2030, but 15% below in 2031 and 34–38% below from 2033, because consensus also carries a higher margin: FactSet's 2033 net income is 32% of revenue against about 30% in our model. Long-dated consensus rests on few models: on fintel's broker counts, 31 analysts forecast 2027 revenue, but only 9–15 go out to 2029–33.

Our 2027 EPS is $5.85 against FactSet consensus of $6.32 (17 November). Under our bridge assumptions, the gap is mostly R&D intensity and the timing of Amicus savings, and the 2027 guide will test it (Appendix Exhibit B1). The 2027 jump in margin and EPS is mostly acquired IPR&D that does not recur. EPS then rises to about $7.8 in 2031, then falls to about $6.8 by 2035 as Vimizim and Palynziq lose exclusivity; the margin peaks near 42% in 2031 and ends near 38%.

Exhibit 12

The 2027 margin step-up is mostly acquired IPR&D not recurring; EPS peaks at ~$7.8 in 2031, then falls to ~$6.8 by 2035 as Vimizim and Palynziq lose exclusivity

Company non-GAAP operating margin (includes acquired IPR&D, as BioMarin reports it), GAAP operating margin and non-GAAP EPS. 2027 onward at a 22% tax rate.

0%40%SBC, amortization and other adjustments23.3%37.8%37.9%Non-GAAP12.7%20.9%23.8%GAAP2027: 2026's $371M acquired IPR&D does not recur$3.152025A$3.072026E$5.852027E$6.602028E$7.102029E$7.332030E$7.792031E$7.322032E$7.192033E$7.172034E$6.762035EFactSet $6.32 · ours 7% lower2027–35 EPS CAGR ~1.8%EPS

2026 carries $371M of acquired IPR&D and Amicus deal costs, which do not recur. Copper marks: FactSet consensus EPS, 17 Nov 2026 (2028–29 not shown).

Copper marks: FactSet consensus non-GAAP EPS via Google Finance, 17 Nov 2026; 2028–29 not shown there. Source: BioMarin filings; Clinaptis base case.


Our SOTP DCF base is $45.54, 20% below the $57.23 price (Exhibit 13). Extra Voxzogo sales carry about a 70% contribution, because R&D and G&A do not grow with them, so each extra $100M of 2032 sales is worth about $1.38 a share: Voxzogo at $1.5B rather than our $1.07B adds about $6, and near $1.9B closes the gap alone. A slower legacy ERT decline adds about $2.70. The enzyme tail sets the DCF's own range: $38.42 if Vimizim's decline starts in 2030 at 20–30% a year, and $49.57 with operating leverage and full savings. (The $39.68–50.14 SOTP row in Exhibit 14 is a separate discount-rate range.) Earnings multiples point higher: BMRN trades at about 10 times our 2027 EPS against a peer median of 15, and peer P/E on our EPS gives $80–99. The weighted value across methods, $56.64, is 1% below the price.

Exhibit 13

BMRN sum of the parts: Voxzogo is worth $13.65 of our $45.54 a share, and Voxzogo near $1.9B by 2032 would close the $11.69 gap to the price

SOTP DCF base by part, $ per diluted share. Extra Voxzogo sales carry about a 70% contribution against the 40% average, so each extra $100M of 2032 sales adds about $1.38 a share; a slower legacy ERT decline (our ERT model's probability-weighted path) adds about $2.71.

$0$10$20$30$40$50$60$70+$13.65Voxzogofranchise+$19.39Amicusproducts+$20.90LegacyERT+$6.50PKUfranchise+$0.59Other+$2.58Pipeline−$18.07Net debt$45.54SOTP DCFbase$57.23+$11.69Price13 NovBMRN value, $ per diluted share
View data
Part$ per share
Voxzogo franchise (achondroplasia, hypochondroplasia, BMN 333, Yuviwel royalty to May 2030)+$13.65
Amicus products (Galafold, Pombiliti + Opfolda)+$19.39
Legacy ERT (Vimizim, Naglazyme, Aldurazyme, Brineura)+$20.90
PKU franchise (Palynziq, Kuvan)+$6.50
Other (Roctavian, legacy royalties)+$0.59
Non-Voxzogo pipeline (flat $0.5B)+$2.58
Net debt ($3.5B)−$18.07
SOTP DCF base$45.54
Price, 13 Nov close$57.23
Gap to price$11.69
Each extra $100M of 2032 Voxzogo sales, at 70% incremental contribution+$1.38
Extra 2032 Voxzogo sales that close the gap alone~$0.84B (to ~$1.9B)
Legacy ERT on our ERT model's probability-weighted Vimizim path+$2.71

Rest-of-company value is split by each group's revenue at a common margin, so the parts add to the total; an allocation, not a product P&L. Legacy ERT = Vimizim, Naglazyme, Aldurazyme, Brineura; PKU = Palynziq, Kuvan. Extra Voxzogo sales ramp to 2032, hold to 2035, then fall 20% a year; at the 40% average margin the gap needs ~$1.5B of extra sales. Methodology: Appendix A2.

Source: Clinaptis Analytical Model, Round 9 (modeled; not observed data).


Exhibit 14

BMRN valuation methods at the 13 November close

Weighted central value $56.64 (range $46.06 to $68.42) against a $57.23 price, −1%. The two cash-flow methods centre on $46 and $56; the earnings multiples on $56 to $88.

$30$40$50$60$70$80$90$100$110SOTP DCFBase case; 10% / 8.5% / 7.5% discount rate$40$5035%DCF to 2035 + exit multiple5x / 7x / 9x 2035 EBIT; 8.5% rate$48$6420%EV / EBITDA, FY27Peer 8.2x / 9.5x / 11.2x on our $1.51B EBITDA$46$6925%P / E, FY27Peer 13.7x / 15.0x / 16.8x on our $5.85 EPS$80$9910%Rare-disease EV / salesPeer 2.7x / 4.7x / 7.0x, less 20%$31$11010%SOTP DCF, enzyme-tail scenarios (memo)Harsh run-off / base / upside with full synergy; 8.5%$38$50P / E on Street EPS (memo)Same peer multiples on the Street $6.32$86$106EV / EBITDA, LTM (memo)Peer 11.3x / 15.7x / 15.7x LTM, BMRN LTM adj. $1.12B$48$73weighttotal 100%Price $57.23Hybrid $56.64 (-1%)
View data
MethodLowCentralHighWeight
SOTP DCF$39.68$45.54$50.1435%
DCF to 2035 + exit multiple$47.59$55.70$63.8020%
EV / EBITDA, FY27$46.36$56.48$69.1325%
P / E, FY27$79.86$87.57$98.5510%
Rare-disease EV / sales$30.78$66.81$109.7410%
Hybrid fair value$46.06$56.64$68.42100%
SOTP DCF, enzyme-tail scenarios (memo)$38.42$45.54$49.57—
P / E on Street EPS (memo)$86.28$94.60$106.47—
EV / EBITDA, LTM (memo)$47.81$73.17$73.33—

Bars run low to high; ticks mark the central case; grey rows carry no weight. Peer prices at 13 Nov closes; FY27 consensus 2–14 Nov. Rare-disease EV/sales carries a 20% discount for size, legacy enzymes and net debt. The weighted value is context, not a target. Methodology: Appendix A2.

Source: Clinaptis Analytical Model; S&P Global consensus via StockAnalysis; FMP consensus via Bigdata.com; BMRN 3Q26 10-Q.


Conclusion

Voxzogo's sales hold near $1.06B through 2032, but the franchise's contribution does not. It falls 10%, from $474M in 2029 to $426M in 2031, when the Yuviwel royalty ends, and recovers only slowly: hypochondroplasia growth just outpaces achondroplasia erosion, and BMN 333 is a token share until Phase 3 shows it beats Voxzogo. Hypochondroplasia paid starts and the ex-US net price have the largest modeled effects on value. Together they cost $2.20 a share in our stress, about 4% of the share price.

BMRN looks cheap on earnings, at about 10 times our 2027 EPS against 15 for peers, and expensive on cash flows: our DCF base of $45.54 is 20% below the price. With its operating leverage, Voxzogo near $1.9B by 2032 would close it alone; the achondroplasia market ceiling puts our forecast at $1.07B. A slower decline in the legacy ERT business, the kind Naglazyme and Aldurazyme have had so far, closes about $2.70. For the franchise, the next tests are the 2027 Voxzogo guide and the first hypochondroplasia payer policies.

Frequently asked questions

What are Voxzogo's projected sales?

We model about $1.07B in 2032. Achondroplasia sales peak at $1,033M in 2028 and fall to $811M; hypochondroplasia adds about $254M after its expected May 2027 approval.

When does BioMarin's Yuviwel royalty end, and what is it worth?

On 20 May 2030. We model about $50M of royalty in 2029, worth about $0.46 a share after tax. Its end cuts modeled franchise contribution about 10%, from $474M in 2029 to $426M in 2031.

How do Voxzogo, Yuviwel and infigratinib compare?

No trial has shown one to be better; the choice turns on dosing (daily injection, weekly injection or oral). Until May 2030 a US switch to Yuviwel returns BioMarin about $21–24 per $100 of lost revenue through the royalty; a switch to oral infigratinib returns nothing.

Will Voxzogo be approved for hypochondroplasia?

The FDA decision is due on 30 May 2027. The randomized Phase 3 showed 2.33 cm a year of extra growth over placebo, and we expect approval. Uptake depends on diagnosis and payer coverage.

What does BioMarin's share price imply for Voxzogo?

Our DCF base is $45.54 against a $57.23 price. Each extra $100M of 2032 Voxzogo sales is worth about $1.38 a share, so Voxzogo near $1.9B by 2032 would close the gap on its own.

Appendix A

A1. BMRN against the NBI, with short interest. Since 8 November 2021: −31.4% against +45.0%. 2026 to date: −3.7% against +26.4%, both to the 13 November close. Short interest was 12.05M shares at the 15 October settlement, the latest FINRA file available at the cutoff, about 6% of shares outstanding.

Exhibit A1

BMRN against the NBI, with short interest

BMRN is ~76pp behind the NBI in five years, and shorts are up fourfold. It is down 31% since Nov 2021 while the Nasdaq Biotechnology Index is up 45%. In 2026 it is down 4% against a 26% gain, with the low in May after Yuviwel’s launch and a 12% fall since the Ascendis settlement. Short interest has roughly quadrupled since early 2024, to 12.05M shares (~6% of shares outstanding), after peaking at 14.3M in July.

BMRN and the NBI, indexed to 100 on 8 Nov 2021

5010015020020222023202420252026NBI 145BMRN 69

BMRN in 2026, with the Voxzogo and deal events

$45$55$65$75JanFebMarAprMayJunJulAugSepOctNovYuviwel approvedAmicus deal closesAscendis settlementQ3 resultsLow $49.67, 18 MayHigh $70.24, 12 Aug$57.23

Shares sold short, twice-monthly FINRA settlements

0M4M8M12M16M202420252026Low 2.96M, Mar 2024Peak 14.3M, 15 Jul 2026 (10.2 days to cover)12.05M4.9 days

Closing prices to 13 Nov 2026 ($57.23); dividends nil. NBI chosen as the benchmark because BMRN is a large-cap constituent; XBI is equal-weighted toward smaller biotechs (+15.4% since 8 Nov 2021). Short interest covers 71 consecutive FINRA settlement dates, 15 Nov 2023 to 15 Oct 2026, the latest settlement file available from FINRA at the 15 Nov cutoff; settlement dates are not publication dates. % of shares outstanding uses 193.7M shares at 30 Sep 2026 and is not a float measure.

Source: Yahoo Finance daily closes (BMRN, ^NBI, XBI), retrieved 6 Nov 2026 and, for 6–13 Nov, 15 Nov 2026; FINRA biweekly short-interest files; BMRN 10-Q.

View data
Period to 13 Nov 2026BMRNNBIRelative
5 years (from 8 Nov 2021)−31.4%+45.0%−76.4pp
1 year+5.6%+31.4%−25.9pp
2026 to date−3.7%+26.4%−30.1pp
Since Yuviwel approval (26 Feb)−6.3%+20.4%−26.8pp
Since Ascendis settlement (27 Aug)−12.3%−1.5%−10.9pp

A2. Methods.

  • Two models. Achondroplasia comes from our market model: eligible children by region × share treated, capped at regional ceilings (US 70%, developed ex-US 75%, rest of world 30%) × drug share × net price. Hypochondroplasia patients come from our earlier patient-flow (switching) model, with 12% annual discontinuation, priced at market-model prices.
  • Prices. Achondroplasia: Voxzogo's US net price is flat at $312k a year; ex-US prices fall 3% a year in developed markets and 2% elsewhere, for all three drugs. Hypochondroplasia uses the same regional Voxzogo revenue per patient: $312k in the US and the market model's ex-US average. Holding US prices flat is generous with three drugs competing; a 3% annual US decline costs $0.53 a share (Exhibit 2). Treated-child growth by quarter (section 3): about 20% in 1Q26 is the figure an analyst put to management on the call, not a number management reported; more than 20% in 2Q26 and 17% in 3Q26 are company-reported.
  • Valuation. 40% contribution margin, 22% tax, 8.5% discount rate, 15% reinvestment; 2026–35 from the franchise run, then −20% a year. The royalty counts at 100% to 20 May 2030 (about $0.46 a share after tax). Our model applies the 18% rate to all ex-US Yuviwel sales, although it covers only the EU, Brazil and South Korea; the whole ex-US royalty is worth about $0.11 a share, so the overstatement is a few cents and we have not rerun for it. At a 30–50% contribution margin the franchise is worth $10.3–17.0 a share; the $48M royalty step barely moves, because product sales are flat over 2029–31.
  • Model history. Our earlier switching model started from about 8,000 Voxzogo patients against about 6,100 observed, so its switching and royalty flows were too large. It had Yuviwel near $900M by 2032 and the royalty at $86M in 2029. The market model, calibrated to today's patients and prices and capped by the eligible pool, has worldwide Yuviwel sales at about $350M in 2032 and the royalty at about $50M. The contribution decline is 10%, against 15% before, and its size depends on how large Yuviwel becomes.
  • Rest of BioMarin. Our company model and DCF, with Galafold and Pombiliti + Opfolda about 20% below management's peak targets and Vimizim on our ERT model's competitive case (Appendix B). Exhibit 13 splits the DCF by product group at a common rest-of-company margin; the gap arithmetic values extra Voxzogo sales at the company model's ~70% incremental contribution (gross margin less variable selling cost).

A3. Exhibit notes. All model values are Clinaptis estimates, not reported figures.

  • Exhibit 1, contribution proxy. 40% of Voxzogo and BMN 333 sales plus the royalty at 100%, pre-tax; BMN 333 carries no separate development cost. The last table row deducts tax and reinvestment. It is not a forecast of BioMarin's reported profit.
  • Exhibit 2, one input at a time. Each case changes only the named inputs. The ex-US price stress reaches both achondroplasia and hypochondroplasia. The combined case ($2.20) is $0.07 less than the sum of its parts ($2.27), because fewer hypochondroplasia patients leave less revenue for the price stress to cut; it is not a ceiling on losses. Upside check: shortening both hypochondroplasia ramps by a year adds about $34M of 2032 sales and $0.26 a share.
  • Exhibit 6, births check. About 3.6M US births a year at a prevalence of 1 in 15,000 to 75,000 gives 50–240 affected children a year, against 150 modeled US starts a year from 2030. Sustaining that rate needs diagnosis of older, undiagnosed children.
  • Exhibit 6, patient math. Treated patients = prior year × 0.88 + new starts. US starts begin in 2027 and reach 150 a year; ex-US starts begin in 2028 and reach 400. BioMarin's disease education has reached more than 1,200 US specialists; it has given no diagnosed-patient count.
  • Exhibit 9, horizon. Contribution as in Exhibit 1; 2026–35 from the market model, then −20% a year in the valuation. BMN 333 launch timing is our assumption.
  • Exhibit 10, not additive. A stress repeated on several rows is one stress. Dates are our judgment where not company-stated; German timings apply the AMNOG statute to Ascendis's planned Q1 2027 launch. BioMarin stops reporting US switching metrics from Q4 2026.
  • Exhibit A4, German detail. The G-BA rated Voxzogo's added benefit as non-quantifiable in 2022, February 2024 and May 2024 (under-2s). Its annual cost after statutory rebates was €225,681 (May 2024). The confidential-price option requires research in Germany; Ascendis's research is in Heidelberg, but it has not said whether it will use the option.

A4. What competition costs BMRN, at 40% and 80% margins. Mechanical sensitivities on the same market-model paths as Exhibit 2, including the no-competition counterfactuals. The 40%-margin values for the shared stresses match Exhibit 2; the 80% column shows the ranking holds at an incremental margin.

Exhibit A4

Ex-US price: from a German Yuviwel price to Voxzogo net price

A German Yuviwel price reaches Voxzogo mainly through Voxzogo’s own German renegotiation, most likely after hypochondroplasia is approved in Europe around 2028. Only then does reference pricing carry a cut to other markets. The Yuviwel price itself may stay confidential.

Germany: Yuviwel’s price process against Voxzogo’s own AMNOG history 2022 2023 2024 2025 2026 2027 2028 2029 Today Confidential-price option: agreements 1 Jan 2025 – 30 Jun 2028 Yuviwel(Ascendis) Voxzogo(BioMarin) EC decisionQ4 2026 (expected) German launchQ1 2027 (planned) G-BA decision ~month 6;price applies from month 7 Price agreed ~Q1 2028;may be confidential ListedOct 2021 Orphan benefit decisionMar 2022 Sales pass €30Mby Nov 2022 Full re-assessmentFeb 2024 Under-2 indicationMay 2024 EMA validates HCH filing2026 HCH re-assessment andrenegotiation, ~2028 Yuviwel ascomparator Observed Company-stated Statutory Our reading Manufacturer’s price Negotiated price
  • Voxzogo's own German agreement is the main channel. EU hypochondroplasia approval would start a new G-BA assessment and price negotiation (our reading: ~2028), with Yuviwel available as a comparator. Germany is the only market with a disclosed revenue floor: Voxzogo passed €30M there in the 12 months to November 2022.
  • Countries that reference Germany would pick up any cut to Voxzogo's German price on their own revision cycles. Switzerland also compares drugs within an indication, every three years and on any indication extension.
  • Tender and contract renewals follow each buyer's cycle. Orders from a single international customer moved BioMarin's 2026 Voxzogo guidance (3Q26).

Yuviwel timings apply the AMNOG statute to Ascendis's planned Q1 2027 launch; the ~2028 re-assessment is our reading. G-BA ratings and prices are observed. Voxzogo's full re-assessment: in February 2024 the G-BA found an indication of non-quantifiable added benefit against best supportive care. Full notes: Appendix A3.

Source: G-BA; § 130b SGB V; GKV-Spitzenverband; BAG; BMRN and Ascendis releases.


Appendix B: the rest of BioMarin

2027 earnings. Our 2027 build reaches $4.42B of revenue, about 1% below the Street's $4.44B (consensus as of 5–6 November), at a 37.8% non-GAAP operating margin and $5.85 of EPS. It includes $26M of Yuviwel royalty in 2027. A 40% margin, the target BioMarin set in 2024 before it bought Amicus, gives $6.27 on consensus revenue; FactSet's $6.32 (17 November) is $0.05 higher. Under our bridge assumptions, the $0.42 gap to $6.27 is mostly cost:

  • R&D intensity: R&D at 17% of sales against 18.4% in our model is worth $0.19;
  • the timing of Amicus savings: $165M in 2027 against $96M in our model is worth $0.27.

In August the CFO gave a rough 2027 estimate of half to slightly more than half of the $220M non-GAAP target, about $110–125M (our arithmetic). In September he said most of the synergies will be realized in 2027, and in November that they were ahead of schedule; full realization remains a 2028 event. The comparable figure in our model is $108M before a stock-based-compensation adjustment ($96M after it). So the August estimate sits close to our model, and the September comment points towards the $165M the Street midpoint implies. BioMarin has yet to quantify 2027 savings after reinvestment. The operating-margin guide can test the EPS bridge even if management gives no separate net savings figure.

We do not have a matched breakdown of analysts' estimates, so this is our reading of what the Street needs, not what it assumes.

  • Supports our view: a margin of 38% or below and EPS of $5.50–5.90, excluding acquired IPR&D.
  • Refutes it: a margin of 40% or above and EPS of $6.20 or more, excluding acquired IPR&D.

BioMarin's non-GAAP EPS includes acquired IPR&D: its 2026 guide fell to $2.80–3.10 after the Alesta acquisition (about $1.55 a share) and the BMN 450 licence (about $0.32). Any 2027 deal would reduce guided EPS in the same way, without telling us anything about the margin.

Exhibit B1

BioMarin’s 2027 EPS: from our $5.85 to FactSet’s $6.32

On $4.44B of consensus revenue and our interest, tax and share-count assumptions, a 40% operating margin gives $6.27; our model has 37.8%. In our bridge, lower R&D adds $0.19 and earlier Amicus savings add $0.27; Street revenue adds $0.07 and a lower gross margin takes back $0.11. FactSet's $6.32 leaves $0.05 our bridge does not explain.

$5.85Clinaptis+$0.07Street revenue−$0.11Gross margin+$0.19R&D+$0.27Amicus savings+$0.05Unexplained$6.32FactSetAxis starts at $4.50
View data
StepEPS effectRunning total
Clinaptis 2027 company non-GAAP EPS—$5.85
Street revenue ($4.44B against $4.42B), at 70.5% incremental contribution+$0.07$5.92
Gross margin at 81.0% against 81.6%−$0.11$5.81
R&D at 17.2% of sales against 18.4%+$0.19$6.00
2027 synergy $165M against $96M (equals a 40.0% margin on $4.44B: $6.27)+$0.27$6.27
Not explained by our bridge+$0.05$6.32
FactSet consensus, 17 Nov 2026—$6.32

Company non-GAAP basis, which keeps acquired IPR&D as a cost; none is assumed in 2027. Interest ($183M), tax (22%) and diluted shares (198.2M) are held at our values. 22% is BioMarin’s recurring non-GAAP tax rate excluding acquired IPR&D (21.8% in 2024, 20.2% in 2025, 24.1% in 1H26). The R&D and synergy steps show what the Street would need, not observed Street assumptions. The axis starts at $4.50.

Source: Clinaptis Analytical Model (modeled; not observed data); consensus 2027 EPS $6.21–6.34 and revenue $4.41–4.46B, 5–6 Nov 2026 snapshots; FactSet EPS via Google Finance, 17 Nov 2026; BMRN 8-K Ex. 99.1, 2Q26–3Q26.


The legacy ERT business.

  • Revenue and patients. Vimizim grew 5.8% in the first nine months of 2026, Naglazyme 2.2% and Palynziq 9.0%. Patients on therapy rose for every product BioMarin markets.
  • Exclusivity. Naglazyme lost exclusivity in 2023 and Aldurazyme in 2020, and neither has eroded. Vimizim's US biologic exclusivity ended in February 2026, and its revenue grew 5.8% in the first nine months (the 18% third-quarter rise reflects order timing, after a 10% fall in the second quarter).

How we model loss of exclusivity. For an ultra-rare ERT, patent expiry and economic loss of exclusivity are different events. Vimizim's principal US patents run to January 2029 and January 2032; in Europe, an SPC runs to April 2029 and a further patent to July 2031. A biosimilar entrant must reproduce a glycosylated enzyme that cells take up through mannose-6-phosphate, then win tenders in several regions; under our cost assumptions it needs about 13% of global Vimizim vials to earn a 12% return, and a US-only launch does not pay. Even so, our base assumes competition takes hold once the patents have expired: Vimizim holds near $950M to 2031, then falls about 17% a year to about $460M by 2035, the competitive case of our ERT model, and about 11% a year after that. Our earlier path (a 20% fall deepening to 30% a year, about $320M by 2035) is now the severe-entry reference; the harsh DCF case starts it in 2030. Our ERT model's probability-weighted path (about $810M in 2035) is the upside to that view, and Naglazyme and Aldurazyme, still growing years after their patents expired, are the evidence for it. Palynziq's US biologic exclusivity ends in 2030; we start its decline in 2032, at 15% a year, to allow time for an entrant.

The DCF cases:

  • harsh enzyme tail (Vimizim's decline starts in 2030 at 20% a year, deepening to 30%; Palynziq, Brineura and Kuvan erode 10–15% a year from assumed triggers; run-off savings): $38.42;
  • base (Vimizim to our ERT model's competitive case and Palynziq declining from 2032, costs flexing with revenue, run-off savings): $45.54;
  • base with operating leverage and full savings: $49.57.

The $57.23 close sits above even the most favourable case. We would revise the forecast on a named biosimilar developer with a filing, a lost Latin American or Middle Eastern tender, or a European price reset at contract renewal. Each would show first as a lower net price on retained patients, not as patients switching.

Exhibit B2

The three key enzyme products: run-rates and our 2027 base

$MFY25 actual9M26 y/yFY26 underlying2027 modelExclusivity
Vimizim (MPS IVA)792+5.8%838880US biologic ended Feb 2026; EU orphan expired
Naglazyme (MPS VI)485+2.2%496506Expired (2023)
Palynziq (PKU)433+9.0%472515US biologic 2030; EU orphan 2029

FY26 underlying = FY25 × (1 + 9M26 growth). 2027 growth assumed at 5%, 2% and 9%. Quarterly revenue swings with large ex-US government orders, so annual figures are the right base.

Source: BMRN 8-K Ex. 99.1, 1Q23–3Q26; FY25 10-K; Clinaptis Analytical Model.


Pipeline. Beyond BMN 333, BioMarin added four programs in 2026. Two are closest to data:

  • BMN 440: an oral ENPP1 inhibitor for hypophosphatasia, a market led by AstraZeneca's Strensiq. PK/PD data due in 2027 will test whether it lowers pyrophosphate without the ectopic calcification seen when ENPP1 is lost.
  • BMN 820: a CCR2 inhibitor for FSGS (US rights). Its Phase 3 reads out in 2028 on an FDA-agreed proteinuria endpoint, behind Travere's Filspari, approved in April 2026.

Our valuation carries the non-Voxzogo pipeline at a flat $0.5B, roughly what BioMarin has paid for it (our estimate).

Additional sources: French national rare-disease registry (BNDMR), achondroplasia and hypochondroplasia birth prevalence, Orphanet J Rare Dis 2025 and ESPE 2025 poster; CANOPY-HCH-3 eligibility, ClinicalTrials.gov NCT06455059; BridgeBio hypochondroplasia Phase 3, NCT06873035; Roberts G, Lewis H, Taylor I, Greenwood M. Evaluating the impact of benefit reassessment outcomes for orphan drugs surpassing the revenue limit in Germany. ISPOR Europe 2024, poster HTA188 (Initiate Consultancy); BioMarin and Genzyme, Aldurazyme joint-venture restructuring release (3 Jan 2008); BioMarin ENDO 2026 release (BMN 333 exposure, company-stated); BioMarin hypochondroplasia disease-education site (age at diagnosis, company-stated); Nature Reviews Endocrinology (prevalence); BioMarin 1Q26, 2Q26 and 3Q26 earnings calls, Morgan Stanley conference (14 Sep 2026) and Stifel fireside (11 Nov 2026) transcripts; Ascendis 3Q26 release and call (12 Nov 2026); BioMarin, 3Q26 results release (2 Nov 2026) and CANOPY-HCH-3 release (9 Sep 2026); Dauber et al., NEJM Evidence (9 Sep 2026), as reported by Healio and Contemporary Pediatrics; ENDO 2026 Phase 2 extension poster; G-BA resolutions on vosoritide (18 Mar 2022, 15 Feb 2024, 16 May 2024); § 130b SGB V and GKV-Spitzenverband guidance on confidential reimbursement amounts; BAG, Spezialitätenliste reference countries; Rémuzat et al. (2015); Cigna and ConnectiCare coverage policies; Ascendis Q3 2026 release (12 Nov 2026); G-BA, Nutzenbewertung nach § 35a SGB V; BioMarin hypochondroplasia disease-education materials; MedlinePlus Genetics and Nature Reviews Endocrinology (prevalence).

This note is research, not investment advice.

BMRN | 17 Nov 2026Clinaptis Research